Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages - PubMed (original) (raw)

. 2012 Aug 15;72(16):4165-77.

doi: 10.1158/0008-5472.CAN-11-2994. Epub 2012 Jun 19.

Steve Schoonooghe, Damya Laoui, Isabelle Houbracken, Wim Waelput, Karine Breckpot, Luc Bouwens, Tony Lahoutte, Patrick De Baetselier, Geert Raes, Nick Devoogdt, Jo A Van Ginderachter

Affiliations

Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages

Kiavash Movahedi et al. Cancer Res. 2012.

Abstract

Tumor-associated macrophages (TAM) are an important component of the tumor stroma and exert several tumor-promoting activities. Strongly pro-angiogenic TAMs that reside in hypoxic tumor areas highly express macrophage mannose receptor (MMR, CD206). In this study, we targeted MMR+ TAMs using nanobodies, which are single-domain antigen-binding fragments derived from Camelidae heavy-chain antibodies. MMR-specific nanobodies stained TAMs in lung and breast tumor single-cell suspensions in vitro, and intravenous injection of 99mTc-labeled anti-MMR nanobodies successfully targeted tumor in vivo. Retention of the nanobody was receptor-specific and absent in MMR-deficient mice. Importantly, co-injection of excess unlabeled, bivalent anti-MMR nanobodies reduced nanobody accumulation in extratumoral organs to background levels, without compromising tumor uptake. Within tumors, the 99mTc-labeled nanobodies specifically labeled MMR+ TAMs, as CCR2-deficient mice that contain fewer TAMs showed significantly reduced tumor uptake. Further, anti-MMR nanobodies accumulated in hypoxic regions, thus targeting pro-angiogenic MMR+ TAMs. Taken together, our findings provide preclinical proof of concept that anti-MMR nanobodies can be used to selectively target and image TAM subpopulations in vivo.

©2012 AACR.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources